'No risk, no fun' : Challenges for the oncology phase I clinical trial time-performanceVERWEIJ, Jaap.European journal of cancer (1990). 2008, Vol 44, Num 17, pp 2600-2607, issn 0959-8049, 8 p.Article

Pazopanib, a new therapy for metastatic soft tissue sarcomaVERWEIJ, Jaap; SLEIJFER, Stefan.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 7, pp 929-935, issn 1465-6566, 7 p.Article

Docetaxel administration schedule : From fever to tears? A review of randomised studiesENGELS, Frederike K; VERWEIJ, Jaap.European journal of cancer (1990). 2005, Vol 41, Num 8, pp 1117-1126, issn 0959-8049, 10 p.Article

Taxane pharmacokineticsSPARREBOOM, Alex; VERWEIJ, Jaap.Investigational new drugs. 2001, Vol 19, Num 2, issn 0167-6997, 87 p.Serial Issue

Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular abberationsVERWEIJ, Jaap; BAKER, Laurence H.European journal of cancer (1990). 2010, Vol 46, Num 5, pp 863-868, issn 0959-8049, 6 p.Article

Role of formulation vehicles in taxane pharmacologyVAN ZUYLEN, Lia; VERWEIJ, Jaap; SPARREBOOM, Alex et al.Investigational new drugs. 2001, Vol 19, Num 2, pp 125-141, issn 0167-6997Article

THE ERA OF GENOMICS-DRIVEN CANCER MEDICINEGARRAWAY, Levi A; VERWEIJ, Jaap; BALLMAN, Karla V et al.Journal of clinical oncology. 2013, Vol 31, Num 15, issn 0732-183X, 112 p.Serial Issue

The art of successful publication ECCO 13 workshop reportSMYTH, John; VERWEIJ, Jaap; D'INCALCI, Maurizio et al.European journal of cancer (1990). 2006, Vol 42, Num 4, pp 434-436, issn 0959-8049, 3 p.Article

Clinical pharmacokinetics of docetaxel : Recent developmentsBAKER, Sharyn D; SPARREBOOM, Alex; VERWEIJ, Jaap et al.Clinical pharmacokinetics. 2006, Vol 45, Num 3, pp 235-252, issn 0312-5963, 18 p.Article

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGF) targeting angiogenesis inhibitors; A reviewESKENS, Ferry A. L. M; VERWEIJ, Jaap.European journal of cancer (1990). 2006, Vol 42, Num 18, pp 3127-3139, issn 0959-8049, 13 p.Article

Dose-escalation models for combination phase I trials in oncologyHAMBERG, Paul; RATAIN, Mark J; LESAFFRE, Emmanuel et al.European journal of cancer (1990). 2010, Vol 46, Num 16, pp 2870-2878, issn 0959-8049, 9 p.Article

Interaction of Cisplatin with the Human Organic Cation Transporter 2FILIPSKI, Kelly K; LOOS, Walter J; VERWEIJ, Jaap et al.Clinical cancer research. 2008, Vol 14, Num 12, pp 3875-3880, issn 1078-0432, 6 p.Article

The (ir)relevance of plasma protein binding of anticancer drugsSPARREBOOM, Alex; NOOTER, Kees; LOOS, Walter J et al.Netherlands journal of medicine. 2001, Vol 59, Num 4, pp 196-207, issn 0300-2977Article

Body surface area as a determinant of pharmacokinetics and drug dosingSAWYER, Michael; RATAIN, Mark J.Investigational new drugs. 2001, Vol 19, Num 2, pp 171-177, issn 0167-6997Article

Personalizing Oncology: Perspectives and ProspectsMENDELSOHN, John.Journal of clinical oncology. 2013, Vol 31, Num 15, pp 1904-1911, issn 0732-183X, 8 p.Article

Renal toxicities of chemotherapyDE JONGE, Maja J. A; VERWEIJ, Jaap.Seminars in oncology. 2006, Vol 33, Num 1, pp 68-73, issn 0093-7754, 6 p.Article

Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matricesSOEPENBERG, Otto; DE BRUIJN, Peter; VERWEIJ, Jaap et al.Journal of chromatography. B. 2004, Vol 799, Num 1, pp 15-22, issn 1570-0232, 8 p.Article

Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolismDE BRUIJN, Peter; KEHRER, Diederik F. S; VERWEIJ, Jaap et al.Journal of chromatography. B, Biomedical sciences and applications. 2001, Vol 753, Num 2, pp 395-400, issn 1387-2273Article

Pharmacological effects of formulation vehicles: Implications for cancer chemotherapyTEN TIJE, Albert J; VERWEIJ, Jaap; LOOS, Walter J et al.Clinical pharmacokinetics. 2003, Vol 42, Num 7, pp 665-685, issn 0312-5963, 21 p.Article

Oral delivery of taxanesMALINGRE, Mirte M; BEIJNEN, Jos H; SCHELLENS, Jan H. M et al.Investigational new drugs. 2001, Vol 19, Num 2, pp 155-162, issn 0167-6997Article

Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: Results of a pharmacokinetic studyKITZEN, Jos J; PUOZZO, Christian; DE JONGE, Maja J et al.European journal of cancer (1990). 2010, Vol 46, Num 2, pp 266-269, issn 0959-8049, 4 p.Article

Population pharmacokinetics of cisplatin in adult cancer patientsDE JONGH, Felix E; GALLO, James M; SHEN, Meiyu et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 2, pp 105-112, issn 0344-5704, 8 p.Article

Clinical pharmacokinetics of irinotecan and its metabolites: A population analysisRUJIA XIE; MATHIJSSEN, Ron H. J; SPARREBOOM, Alex et al.Journal of clinical oncology. 2002, Vol 20, Num 15, pp 3293-3301, issn 0732-183XArticle

Diagnostic imagingHERRLIN, K; PETTERSSSON, H.Cancer treatment and research. 1993, Vol 67, pp 57-79, issn 0927-3042Article

Genomics-Driven Oncology: Framework for an Emerging ParadigmGARRAWAY, Levi A.Journal of clinical oncology. 2013, Vol 31, Num 15, pp 1806-1814, issn 0732-183X, 9 p.Article